VENLO, Netherlands--(

文洛，荷兰--(

BUSINESS WIRE

商业热线

)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a significant increase in the powerful capabilities of its QIAcuity Digital PCR (dPCR) system with a more than two-fold increase in the number of targets that can be simultaneously analyzed from a single biological sample.

)--QIAGEN（纽约证券交易所：QGEN；法兰克福主要标准：QIA）今天宣布，其QIAcuity数字PCR（dPCR）系统的强大功能显着增强，可以同时从单个生物样品中分析的靶标数量增加了两倍以上。

The new capabilities overcome the assay design challenges of currently available quantitative multiplex PCR methods, making QIAcuity digital PCR ideal for applications such as translational research, microbiome analysis, pathogen detection and the development of cell and gene therapies.

新功能克服了目前可用的定量多重PCR方法的测定设计挑战，使QIAcuity数字PCR成为翻译研究，微生物组分析，病原体检测以及细胞和基因疗法开发等应用的理想选择。

Through a software upgrade and the launch of the new QIAcuity High Multiplex Probe PCR Kit, customers can now analyze up to 12 targets simultaneously compared to the earlier version offering up to five targets, using their existing instruments without any hardware changes.

通过软件升级和推出新的QIAcuity High Multiplex Probe PCR Kit，客户现在可以同时分析多达12个目标，而早期版本可以提供多达5个目标，使用现有仪器而无需任何硬件更改。

This upgrade provides QIAcuity customers with a powerful technology that amplifies and detects multiple targets within a single reaction. By combining multiple PCR assays, researchers can now maximize sample use while simultaneously reducing time and reagent consumption that accelerates the process to obtain deep biological insights..

此升级为QIAcuity客户提供了一种强大的技术，可以在单个反应中放大和检测多个目标。通过结合多种PCR检测，研究人员现在可以最大限度地使用样品，同时减少时间和试剂消耗，从而加速获得深入生物学见解的过程。。

“Analyzing more targets simultaneously from a single biological sample is an important step in making QIAcuity even more the top choice for groundbreaking dPCR applications,” said Nitin Sood, Senior Vice President and Head of the Life Sciences Business Area at QIAGEN. “We are exploring ways to further increase the capabilities of QIAcuity to help researchers gain a deeper biological understanding of any sample type in a cost-efficient way without tedious optimization or fear of inaccurate quantification.”.

QIAGEN高级副总裁兼生命科学业务领域负责人Nitin Sood表示：“同时从单个生物样本中分析更多目标是使QIAcuity成为开创性dPCR应用的首选的重要一步。”。“我们正在探索进一步提高QIAcuity能力的方法，以帮助研究人员以经济高效的方式对任何样本类型获得更深入的生物学理解，而无需繁琐的优化或担心量化不准确。”。

The adoption of QIAcuity digital PCR research instrument is strong, with more than 2,700 cumulative placements at the end of 2024 and citations in over 550 publications. Key customers include pharmaceutical and biotechnology companies, academic and research organizations and forensic laboratories. In the fall of 2024, QIAGEN expanded its dPCR portfolio into clinical testing with the launch of QIAcuityDx, which is designed to address clinical customer segments and applications and to further strengthen the QIAcuity family..

QIAcuity digital PCR research instrument的采用率很高，到2024年底累计有2700多个职位，在550多篇出版物中被引用。主要客户包括制药和生物技术公司、学术和研究组织以及法医实验室。2024年秋季，QIAGEN推出了QIAcuityDx，将其dPCR产品组合扩展到临床测试领域，旨在解决临床客户细分和应用问题，并进一步加强QIAcuity家族。。

The QIAcuity High Multiplex Probe PCR Kit contains a ready-to-use master mix optimized for microfluidic use in the QIAcuity Nanoplates and lets users conveniently perform high-order multiplexing on existing QIAcuity instruments. The kit enhances the specificity and efficiency of probe-based digital PCR to provide accurate singleplex, or up to 12-plex analysis..

QIAcuity High Multiplex Probe PCR Kit包含一个现成的主混合物，该混合物针对QIAcuity纳米板中的微流体使用进行了优化，使用户可以方便地在现有QIAcuity仪器上执行高阶多路复用。该试剂盒增强了基于探针的数字PCR的特异性和效率，以提供准确的单重或多达12重分析。。

As a prerequisite to use the QIAcuity High Multiplex Probe PCR Kit, the QIAcuity Software 3.1 introduces essential features for high-order multiplexing such as crosstalk compensation which corrects signal overlap between targets. This enables researchers to confidently analyze more targets in parallel from one undivided sample..

作为使用QIAcuity High Multiplex Probe PCR试剂盒的先决条件，QIAcuity软件3.1引入了高阶多路复用的基本功能，例如串扰补偿，可校正目标之间的信号重叠。这使研究人员能够自信地从一个不可分割的样本中并行分析更多目标。。

QIAcuity dPCR catalog and custom assays for copy number variation (CNV) analysis and microbial detection have been re-designed to support up to 12-plex reactions. These assays are available through QIAGEN’s GeneGlobe platform.

QIAcuity dPCR目录和用于拷贝数变异（CNV）分析和微生物检测的定制分析已被重新设计，以支持多达12个复杂的反应。这些测定可通过QIAGEN的GeneGlobe平台获得。

The combination of sophisticated software and innovative chemistry make QIAcuity dPCR a superior solution for high-order multiplexing. It enhances workflows by offering greater target capacity and improved data reliability while QIAcuity remains the dPCR system with the highest throughput and is highly automation-friendly..

复杂软件和创新化学的结合使QIAcuity dPCR成为高阶多路复用的优越解决方案。它通过提供更大的目标容量和更高的数据可靠性来增强工作流程，而QIAcuity仍然是dPCR系统中吞吐量最高且自动化程度高的系统。。

QIAGEN's QIAcuity digital PCR platform utilizes nanoplates to disperse a sample into thousands of tiny partitions and then reads the reaction in each one simultaneously to quantify even the faintest signals from DNA and RNA. The platform integrates partitioning, thermocycling, and imaging into a streamlined multiplex workflow, reducing processing times from six hours to just two.

QIAGEN的QIAcuity数字PCR平台利用纳米板将样品分散到数千个微小的分区中，然后同时读取每个分区中的反应，以量化甚至是来自DNA和RNA的最微弱信号。该平台将分区，热循环和成像集成到一个简化的多重工作流程中，将处理时间从六个小时减少到只有两个小时。

Available in one-, four-, and eight-plate versions, the platform meets the needs of a wide range of laboratory sizes and throughput requirements..

该平台有单板、四板和八板版本，可满足各种实验室规模和吞吐量要求。。

For more information about QIAcuity’s new multiplexing capabilities, please visit:

有关QIAcuity新多路复用功能的更多信息，请访问：

https://www.qiagen.com/applications/digital-pcr/beginners/dpcr-multiplexing

https://www.qiagen.com/applications/digital-pcr/beginners/dpcr-multiplexing

About QIAGEN

关于QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials.

QIAGEN N.V.是一家总部位于荷兰的控股公司，是全球领先的样本到见解解决方案提供商，该解决方案使客户能够从包含生命构建模块的样本中获得有价值的分子见解。我们的样品技术从血液、组织和其他材料中分离和处理DNA、RNA和蛋白质。

Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics).

分析技术使这些生物分子可见并准备进行分析。生物信息学软件和知识库解释数据以报告相关的可行见解。自动化解决方案以无缝且经济高效的工作流将这些功能结合在一起。QIAGEN在分子诊断（人类保健）和生命科学（学术界、制药研发和工业应用，主要是法医学）方面为全球50多万客户提供解决方案。

As of September 30, 2024, QIAGEN employed more than 5,800 people in over 35 locations worldwide. Further information can be found at .

截至2024年9月30日，QIAGEN在全球35多个地点雇用了5800多人。。

https://www.qiagen.com

https://www.qiagen.com

.

.

Forward-Looking Statement

前瞻性声明

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, collaborations, markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks.

本新闻稿中的某些声明可能被视为1933年《美国证券法》第27A节（经修订）和1934年《美国证券交易法》第21E节（经修订）所指的前瞻性声明。如果本文中包含的与QIAGEN产品、发布和开发时间、营销和/或监管批准、财务和运营前景、增长和扩张、合作、市场、战略或运营结果（包括但不限于其预期的调整后净销售额和调整后的稀释收益结果）有关的任何报表都是前瞻性的，则此类报表基于当前的预期和假设，涉及许多不确定性和风险。

Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competito.

此类不确定性和风险包括但不限于与增长管理和国际运营相关的风险（包括货币波动的影响、监管流程和对物流的依赖）、经营成果的可变性和客户类别之间的分配、我们的产品在学术界、制药、应用测试和分子诊断领域的客户市场的商业开发；改变与客户、供应商和战略合作伙伴的关系；竞争；技术的快速或意外变化；QIAGEN产品需求波动（包括一般经济状况、客户资金水平和时间、预算和其他因素引起的波动）；；成功将QIAGEN的产品应用于集成解决方案并生产此类产品的困难；QIAGEN识别和开发新产品的能力，以及区分和保护我们的产品免受竞争的能力。

Source: QIAGEN N.V.

资料来源：QIAGEN N.V。

Category: Corporate

类别：公司